These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8549321)

  • 1. Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa.
    Sato A; Kitazawa H; Chida K; Hayakawa H; Iwata M
    Drugs; 1995; 49 Suppl 2():253-5. PubMed ID: 8549321
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
    Sato A; Kitazawa H; Hayakawa H; Chida K; Iwata M
    J Antimicrob Chemother; 1997 Feb; 39(2):217-22. PubMed ID: 9069542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract]   [Full Text] [Related]  

  • 4. Grepafloxacin--focus on respiratory infections.
    Geddes AM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():1-4. PubMed ID: 9484866
    [No Abstract]   [Full Text] [Related]  

  • 5. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997].
    Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540
    [No Abstract]   [Full Text] [Related]  

  • 6. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
    Spivey IM
    Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin.
    Growcott EJ; Coulthard A; Amison R; Hardaker EL; Saxena V; Malt L; Jones P; Grevot A; Poll C; Osborne C; Banner KH
    J Cyst Fibros; 2011 May; 10(3):166-74. PubMed ID: 21247812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prulifloxacin. NAD-441A, NM 441, Quisnon.
    Drugs R D; 2002; 3(6):426-30. PubMed ID: 12516950
    [No Abstract]   [Full Text] [Related]  

  • 9. Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.
    Collie D; Glendinning L; Govan J; Wright S; Thornton E; Tennant P; Doherty C; McLachlan G
    PLoS One; 2015; 10(11):e0142097. PubMed ID: 26544950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of Baytril (Bay Vp 2674) on young turkeys with respiratory tract infections].
    Braunius WW
    Tijdschr Diergeneeskd; 1987 May; 112(9):531-3. PubMed ID: 3603541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
    Niki Y; Tamada S; Nakabayashi M; Soejima R
    Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
    [No Abstract]   [Full Text] [Related]  

  • 12. Susceptibility to new quinolones of Pseudomonas aeruginosa isolated from a patient with chronic respiratory tract infection.
    Goto H; Adachi F; Minamoto F; Suzuki M; Shimada K; Ieki R; Okamura T; Iguchi M; Yuasa K
    Drugs; 1995; 49 Suppl 2():177-8. PubMed ID: 8549294
    [No Abstract]   [Full Text] [Related]  

  • 13. Short communication. Role of agar beads in the pathogenicity of Pseudomonas aeruginosa in the rat respiratory tract.
    Nacucchio MC; Cerquetti MC; Meiss RP; Sordelli DO
    Pediatr Res; 1984 Mar; 18(3):295-6. PubMed ID: 6728563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model.
    Araki N; Yanagihara K; Morinaga Y; Yamada K; Yamada Y; Kohno S; Kamihira S
    J Infect Chemother; 2011 Jun; 17(3):318-21. PubMed ID: 20972597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rat model of chronic respiratory infection with Pseudomonas aeruginosa.
    Cash HA; Woods DE; McCullough B; Johanson WG; Bass JA
    Am Rev Respir Dis; 1979 Mar; 119(3):453-9. PubMed ID: 109021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significant role of newer quinolone antimicrobials in respiratory tract infection: focused on sparfloxacin].
    Jpn J Antibiot; 1994 Oct; 47(10):1241-58. PubMed ID: 7807686
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessing Pseudomonas aeruginosa virulence and the host response using murine models of acute and chronic lung infection.
    Kukavica-Ibrulj I; Facchini M; Cigana C; Levesque RC; Bragonzi A
    Methods Mol Biol; 2014; 1149():757-71. PubMed ID: 24818948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of a new quinolone, DW-116.
    Lee DK
    Drugs; 1995; 49 Suppl 2():323-5. PubMed ID: 8549349
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
    Lu Q; Yu J; Bao L; Ran T; Zhong H
    Chemotherapy; 2013; 59(1):51-6. PubMed ID: 23816803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two new fluoroquinolones.
    Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.